• 01Company
    Company
    Vision and Values
    Citizenship
    Leadership Team
    Board of Directors
    Our Locations
  • 02Products & Services
    Products
    R&D
    Generics
    Export Oncology
    Facilities
    Contract Research
  • 03Investors
    Investors
    Corporate Governance
    Monthly Sales
    Quarterly Results
    Shareholders Services
    Financial Calendar
  • 04Newsroom
Contact Us
Language
Languages
  • English
  • Chinese
  • Alvogen Korea
Contact Us
Language
Languages
  • English
  • Chinese
  • Alvogen Korea
Newsroom
Company
Vision and Values
Citizenship
Leadership Team
Board of Directors
Our Locations
Products
R&D
Generics
Export Oncology
Facilities
Contract Research
Investors
Corporate Governance
Monthly Sales
Quarterly Results
Shareholders Services
Financial Calendar
Skip Navigation
Newsroom

Featured News

  • Business
    05 September 2022

    Lotus Launches Lenalidomide Capsules 5mg, 10mg, 15mg, and 25mg, Generic Version of Revlimid® in the US

  • Business
    16 January 2023

    Lotus Obtains Tentative Approval for Nintedanib ANDA from the US FDA

  • Investors
    10 January 2023

    Lotus Ends 2022 on a Strong Note, with Full Year Revenue up 15.7% over Last Year

  • Business
    05 January 2023

    Lotus Obtained Another Exclusive Right of Cancer Injectable Drug Across Asia

  • Business
    29 December 2022

    Alvogen Korea ISO37001 (ANTI-BRIBERY MANAGEMENT SYSTEM) certification renewal

  • Business
    13 December 2022

    Lotus acquires Alimta® (Pemetrexed) in Taiwan from Lilly

  • Investors
    09 December 2022

    Monthly sales report for November 2022

  • Business
    01 December 2022

    Lotus Received Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) 2022

  • Business
    30 November 2022

    Alvogen Korea held a meeting with the Iceland Minister of Culture and Business Affairs during her visit to Korea

  • Investors
    10 November 2022

    Lotus Reports Its Best Quarter Ever With the Biggest Launch in Its History

  • Company
  • Products & Services
  • Investors
  • Newsroom
  • Contact Us
    • Privacy Policy
    • Terms of Use

    © 2021 Lotus. All Rights Reserved